CRANFORD, N.J., March 16, 2011 /PRNewswire/ — Coronary artery
disease (CAD), also known as coronary heart disease, is the most
common type of heart disease, currently affecting about 17 million
Americans(1). Most of these people suffer from a common symptom of
CAD known as angina pectoris. For over 100 years, physicians have
treated acute angina with nitrates, the most common form being
nitroglycerin(2). Considered the gold standard in treating acute
angina, nitroglycerin tablets have had problems with diminished
stability and potency once dispensed(3-5). In recent years,
nitroglycerin sprays were introduced and have alleviated much of
the potency and stability concerns associated with the storage of
tablets. Studies have shown that nitroglycerin sprays are capable
of providing a more rapid form of symptom relief in most angina
patients(6).
NitroMist® (Nitroglycerin
Lingual Aerosol 400 mcg) is indicated for acute relief of an attack
or acute prophylaxis of angina pectoris due to coronary artery
disease. It provides nitroglycerin in a rapidly absorbed,
mentholated spray formulation, specifically designed for use on or
under the tongue. NitroMist is available in a fully sealed aerosol
delivery system, providing a shelf life of 36 months. NitroMist
contains no ethyl alcohol.
Nitroglycerin sprays are proven to relieve the symptoms of
angina significantly faster than tablets in most patients(6).
Wayne Anderson, Akrimax’ President and CEO stated, “Akrimax is
committed to providing health care providers and their patients
with therapies that can make an important difference in the lives
of patients. We believe NitroMist is an excellent example of this.
NitroMist is the second new product that Akrimax has brought to
market in the past year. Akrimax also has expanded its sales force
by a third in order to educate health care providers about
NitroMist and its other promoted brands, Tirosint and Inderal
LA.
‘/>”/>
